Immunome IMNM
$ 10.9
-1.62%
Quarterly report 2024-Q3
added 11-13-2024
Immunome Balance Sheet 2011-2024 | IMNM
Annual Balance Sheet Immunome
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | -39.2 M | -2.22 M | -1.05 M | - | - | - | - | - | - | - |
Long Term Debt |
- | - | - | 134 K | 113 K | 325 K | - | - | - | - | - | - | - |
Long Term Debt Current |
- | - | - | 366 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 142 K | 39 M | 28.1 M | - | - | - | - | - | - | - |
Total Current Liabilities |
21.8 M | 7.33 M | 9.73 M | 3.04 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
28.7 M | 7.39 M | 9.74 M | 3.18 M | 40.7 M | 29.7 M | - | - | - | - | - | - | - |
Deferred Revenue |
10.5 M | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-223 M | -116 M | -79.1 M | -54.4 M | -36.6 M | -26.1 M | - | - | - | - | - | - | - |
Total Assets |
149 M | 24 M | 57.9 M | 44.5 M | 5.06 M | 4.45 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
98.7 M | 20.3 M | 49.2 M | 39.8 M | 2.64 M | - | - | - | - | - | - | - | - |
Book Value |
120 M | 16.7 M | 48.2 M | 41.3 M | -35.6 M | -25.2 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
120 M | 16.7 M | 48.2 M | 41.3 M | -35.6 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Immunome
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
2.46 M | 2.48 M | 1.21 M | 1.34 M | - | - | - | - | - | - | - | - | - | - | 134 K | 134 K | 134 K | 134 K | 134 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
42 M | 42.4 M | 34.2 M | 28.7 M | 87.1 M | 32.1 M | 34.3 M | 7.39 M | 7.46 M | - | 9.85 M | 9.74 M | 7.76 M | 3.52 M | 4.71 M | 3.18 M | 3.18 M | 3.18 M | 3.18 M | 1.8 M | 1.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
9.68 M | 12.6 M | 12.7 M | 10.5 M | 17 M | 17.7 M | 18.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-436 M | -388 M | -352 M | -223 M | -130 M | -126 M | -120 M | -116 M | -108 M | - | -90.8 M | -79.1 M | -71.3 M | -63.5 M | -58.3 M | -54.4 M | -54.4 M | -54.4 M | -54.4 M | -36.6 M | -36.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
257 M | 296 M | 320 M | 149 M | 93.2 M | 41.4 M | 48.1 M | 24 M | 30.5 M | - | 47.7 M | 57.9 M | 62.6 M | 64.1 M | 42.6 M | 44.5 M | 44.5 M | 44.5 M | 44.5 M | 5.06 M | 5.06 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
156 M | 165 M | 270 M | 98.7 M | 90.6 M | 38.4 M | 44.4 M | 20.3 M | 27.1 M | 34.6 M | 42.9 M | 49.2 M | 56.2 M | 59.8 M | 36.3 M | 39.8 M | 39.8 M | 39.8 M | 39.8 M | 2.54 M | 2.54 M | - | - | 1.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
215 M | 254 M | 286 M | 120 M | 6.08 M | 9.34 M | 13.9 M | 16.7 M | 23.1 M | - | 37.9 M | 48.2 M | 54.8 M | 60.6 M | 37.9 M | 41.3 M | 41.3 M | 41.3 M | 41.3 M | 3.26 M | 3.26 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
215 M | 254 M | 286 M | 120 M | 6.08 M | 9.34 M | 13.9 M | 16.7 M | 23.1 M | 30.3 M | 37.9 M | 48.2 M | 54.8 M | 60.6 M | 37.9 M | 41.3 M | 41.3 M | 41.3 M | 41.3 M | -35.6 M | -35.6 M | -30 M | - | -25.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency